Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/01/2789228/0/en/Foghorn-Therapeutics-Announces-Clinical-Data-from-Phase-1-Study-of-FHD-286-a-Novel-BRG1-BRM-Inhibitor-in-Patients-with-Advanced-Hematologic-Malignancies-to-be-Presented-at-American.html

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2023, in San Diego, California.

Read more at globenewswire.com

Related news for (FHTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.